Navigation Links
NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
Date:9/26/2007

Company to develop for treatment of neurofibromatosis and cancer

NEW YORK, Sept. 26 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc., a privately held New York biotechnology company focused on developing drugs to treat the genetic disorder neurofibromatosis and related sporadic tumors, today announced that it has entered into a definitive agreement with Universite Louis Pasteur (ULP) and the Centre National de la Recherche Scientifique (CNRS) to in-license a novel family of Hsp90 inhibitors.

"Our preliminary evaluation of these compounds has yielded promising results in NF2 and cancer models", said Dr. Allan Rubenstein, CEO of NexGenix. "While targeting the inhibition of protein folding chaperones such as Hsp90 is an approach that is seeing success in clinical trials for cancer, this target has additionally been shown to be potentially promising for a number of therapeutic indications. We intend to evaluate this compound series for the treatment of several disorders."

Under the terms of this agreement, NexGenix will have an exclusive worldwide license to develop and commercialize the technology for human and animal therapeutic and diagnostic use from ULP and CNRS. NexGenix will be responsible for all development and commercialization costs and activities. In return, ULP and CNRS will be entitled to certain maintenance fees, milestone payments and royalties.

The company has additionally entered into a Collaborative Research Agreement with the Institut de Sciences et d'Ingenierie Supramoleculaires at ULP to further understanding of structure activity relationships and opportunities to improve the pharmacokinetic properties of the in-licensed Hsp90 inhibitor compound series. This research program is to be conducted at ULP by Nicolas Winssinger, PhD. Dr. Winssinger is one of the inventors of the compound series and is a member of the NexGenix Scientific Advisory Board.

About NexGenix Pharmaceuticals

NexGenix Pharmaceu
'/>"/>

SOURCE NexGenix Pharmaceuticals Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. WARF enters licensing agreements for stem cell products
4. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
5. Software company enters health space with RFID solutions on hold
6. Lucigen Corp. enters global licensing agreement
7. Call centers and customer service: The good, the bad, and the clueless
8. GE Healthcare enters agreement with Canadian health authority
9. Data centers: Buyers beware of over-hyped facilities
10. Data centers: Blowing smoke and raising red flags
11. Prodesse enters patent agreement with Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Patheon Inc ., a leading provider ... pharmaceutical industry, will host a complimentary webinar on “Cleaning ... Tuesday, June 4, 2013 at 11 a.m. Eastern Standard ... comply with regulations for cleaning validation. Many companies ... and little evaluation of risk. Some companies have ...
(Date:5/23/2013)... Calif. , May 23, 2013 ... a strategic alliance with DAK Renewable Research to ... corn oil yield. VG Energy is a majority ... Pink: VGLS). VG Energy,s exclusively licensed ... increase the oil yield in plants, possessing a ...
(Date:5/23/2013)... 2013 Z Trim Holdings, Inc. (OTC Markets: ... variety of industries, announced that Chef Erin ... this year,s National Restaurant Association ("NRA") NRA Show, which ... the Research Chefs Association.  Chef Ryan spoke on the ... Bad and the Ugly," joining four other prestigious panelists ...
(Date:5/23/2013)... 2013 During the conduct of ... adhere to principles of good clinical practice (GCP) ... Dr. Jeremy Lim, Fellow, Clinical Development at Novartis ... ,     Understand the International Conference on Harmonization (ICH) ... regulations for the conduction of clinical trials , ...
Breaking Biology Technology:Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
... , , MONTRÉAL, Jan. 19 ... it has established a Special Committee of independent Board members ... limited to, a sale of the Company or the sale ... Committee will be working with management and external consultants to ...
... ... Awards are granted based on ease of integration, functionality, innovation, manageability, performance and value ... ... has received the SearchServerVirtualization 2009 Silver Award for Virtualization Management. ...
... , NEW HAVEN, Conn. , Jan. 19 ... appointed Dr. Richard J. Carroll to the newly ... brings to HistoRx over 20 years of sales, marketing, research, ... device industries. Before joining HistoRx in 2009, he was Vice ...
Cached Biology Technology:ConjuChem to evaluate strategic alternatives 2VKernel's Optimization Pack Wins Award In SearchServerVirtualization.Com's 2009 Products of the Year Survey 2HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 2HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 3
(Date:5/22/2013)... May 22, 2013 U.S. Forest Service scientists are ... with funding from the TKF Foundation, will examine how ... and individuals recover from tragedy. , The TKF Foundation ... six projects selected for grant funding. In addition to ... spaces in recovery and resiliency, the 3-year, $585,000 grant ...
(Date:5/22/2013)... and engineers must join together in a major new ... a crisis in providing Earth,s people with clean water ... focus of a comment article in the current edition ... newsmagazine of the American Chemical Society (ACS), the world,s ... L. Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain ...
(Date:5/22/2013)... changes in cellular DNA can endanger the whole organism, ... Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich now report how ... double helix. , The DNA in our cells controls ... our bodies. The instructions for this are encoded in ... DNA, the bases adenine (A), cytosine (C), guanine (G) ...
Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2DNA damage: The dark side of respiration 2
... can never give accurate results. Whether you,re about to lean in ... asking a trusted friend if your breath is sweet. But what ... Tel Aviv University researchers have come up with the ultimate solution ... bacteria are brewing in your mouth. A blue result suggests you ...
... Approximately 350 million to 500 million cases of malaria ... While medications to prevent and treat malaria do exist, ... in part, because malaria parasites have developed a resistance ... Hopkins University School of Medicine have discovered one way ...
... in College of Life Science, Zhejiang University, has shown ... island has a parental differentially methylated region (DMR). These ... exists in lower vertebrates and genomic imprinting should not ... The study is reported in volume 54 (Issue 8, ...
Cached Biology News:Are you okay to kiss? 2Are you okay to kiss? 3New lead on malaria treatment 2The evolutionary foundation of genomic imprinting in lower vertebrates 2
Recombinant Rat Fas Ligand/TNFSF6...
Request Info...
FGF Receptor 1 Antibody...
... Anti-Na + /K + ATPase α-1, ... NM_001001586 Immunogen : Purified Na + ... fractions of rabbit kidney outer medulla Formulation: ... 0.05% sodium azide Quality Assurance: routinely evaluated ...
Biology Products: